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Hodgkin’s lymphoma; RA = rheumatoid arthritis; SLL = small lymphocytic lymphoma.
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Abstract
A substantial body of data supports use of rituximab as first-line
and maintenance therapy for the treatment of indolent non-
Hodgkin’s lymphoma. With 7 years of postmarketing surveillance
experience and more than 370,000 patient exposures, the safety
profile of rituximab is well defined. Several multicenter trials
suggest that infusion reactions associated with rituximab
administration are well characterized and generally associated with
the first infusion; toxicity is reduced with subsequent doses. Since
some adverse events are related to circulating tumor loads of non-
Hodgkin’s lymphoma, fewer events are anticipated in rheumatoid
arthritis. Low infection rates in oncology would indicate similar
safety in patients with rheumatoid arthritis.
Introduction
The US Food and Drug Administration (FDA) approved the
chimeric anti-CD20 monoclonal antibody rituximab in 1997 as
a single-agent treatment for relapsed or refractory, low grade
or follicular CD20+, B cell non-Hodgkin’s lymphoma (NHL). In
as many as 85% patients, NHL is of B cell origin, and a
majority has high affinity expression for CD20. For that reason,
rituximab is now widely used in hematologic oncology.
Almost half a million patients have been treated with
rituximab, either alone or in combination, from phase II and III
of development through postmarketing approval. Although
not formally approved for use in combination protocols by the
FDA, rituximab is now included in a standard-of-care, in
combination with CHOP (cyclophosphamide, doxorubicin,
vincristine, and prednisone) chemotherapy, for treatment of
aggressive lymphomas of B cell origin.
In the original clinical studies, patients received four weekly
doses of 375 mg/m2; this dosage schedule increased to
eight weekly infusions of 375 mg/m2 in subsequent trials. The
choice of cumulative dosage was somewhat arbitrarily based
on biologic factors. Doctors frequently give extended courses
of rituximab (four to eight courses instead of the standard
single 4-week course) to those patients who have not
reached dose limiting toxicity.
Overall, rituximab has exhibited very strong and consistent
efficacy alone and in combination with virtually all of the
chemotherapeutic agents used to treat B cell lymphomas.
This has resulted in a very large safety database, permitting
accurate assessment of the nature of the specific side effects
and risks involved in using this drug.
Safety of rituximab
A substantial and growing body of data illustrates the safety
of rituximab when used as first-line treatment and mainten-
ance therapy for NHL. Although responses in a rheumatoid
arthritis (RA) population are different from those in NHL
patients, knowledge gained in the oncology setting may be of
significant relevance to treatment of RA patients.
McLaughlin and coworkers [1] described the safety profile of
rituximab monotherapy in a pivotal phase III study conducted in
relapsed and refractory indolent NHL. In that trial patients with
relapsing low grade or follicular lymphoma received, on an
outpatient basis, intravenous rituximab 375 mg/m2 weekly for
4 weeks. A total of 166 patients were enrolled in the trial, with
an approximately 48% response rate. With a median follow up
of 11.8 months, the authors observed that among responders
the projected time to progression was 13.0 months.
The majority of adverse events (AEs), which were grade 1 and
2 in severity, occurred during the first infusion period, with fever
and chills being the most common symptoms. Only 12% of
patients had grade 3 toxicities, and 3% had grade 4 toxicities.
A human antichimeric antibody was detected in only one
patient. The researchers suggested that the toxicity was mild.
The risk factors for severe AEs associated with use of
rituximab are well defined. Moreover, because some of the
Review
B cell non-Hodgkin’s lymphoma: rituximab safety experience
Ann Mohrbacher
Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Correspondence: Ann Mohrbacher, mohrbach@usc.edu
Published: 18 May 2005 Arthritis Research & Therapy 2005, 7(Suppl 3):S19-S25
This article is online at http://arthritis-research.com/content/7/S3/S19 (DOI 10.1186/ar1739)
© 2005 BioMed Central LtdS20
Arthritis Research & Therapy    June 2005 Vol 7 Suppl 3 Mohrbacher
rare AEs of rituximab are related to circulating tumor loads in
NHL, it can be anticipated that they will be less likely to occur
in the RA population.
The AE profile for rituximab has been consistent throughout
numerous subsequent studies in both indolent and
aggressive NHL. Hainsworth and coworkers [2] enrolled 62
patients with indolent follicular or small lymphocytic subtypes
of NHL. These patients, who were previously untreated with
systemic therapy, received intravenous rituximab 375 mg/m2
weekly for 4 weeks. Patients were restaged at week 6 to
assess the response; those with an objective response or
stable disease received maintenance rituximab courses
(identical dose and schedule) at 6-month intervals. The
minimum follow-up period was 24 months. Median actuarial
progression-free survival was 34 months.
The study reported that treatment with rituximab was well
tolerated. Of the 62 patients who received 245 rituximab
doses (four doses per patient), only two developed grade 3
or grade 4 AEs. One patient, the only patient in whom therapy
was discontinued because of treatment-related toxicity, had
flushing, dyspnea, and ischemic chest pain. One additional
patient had severe chills and rigors with the first dose of
rituximab but was able to continue treatment without further
episodes.
The most common grade 1 or 2 toxicities were fever (18%),
chills/rigors (26%), and nausea (21%). Almost all AEs
occurred during the first rituximab infusion. The infusion
reaction also appeared to be related to the tumor load,
suggesting that such reactions might be less likely or severe
in patients with RA. Hainsworth and coworkers [2] reported
that eight patients in the study (13%) had circulating
malignant lymphocyte counts greater than 10,000/µl upon
initiation of treatment. Four of these eight patients
experienced grade 1 or 2 infusion related toxicity during the
first dose of rituximab, but none developed grade 3 or 4
toxicity. The incidence of toxicity in patients older than
70 years was comparable to that in younger patients.
The other grade 1 or grade 2 AEs related to infusions included
flushing (five patients), hypotension (three patients), headache
(three patients), and chest pain, angioedema and broncho-
spasm (one case each). Overall, 18 patients reported fatigue,
four had anemia and two developed leukopenia, all grade 1 or
2 AEs. No cumulative or additional toxicities were seen with
maintenance courses.
French researchers conducted an open label, randomized,
phase II trial to evaluate the clinical efficacy and safety of
rituximab in patients with progressive intermediate or high
grade NHL [3]. Study participants received one of two
dosage schedules of rituximab (all intravenous): 375 mg/m2
once weekly for 8 weeks; and 375 mg/m2 on day 1 followed
by 500 mg/m2 on day 8 and once weekly for a further
7 weeks. Rituximab was administered via a peripheral or
central intravenous line in an outpatient setting. Infusion was
started at an initial rate of 50 mg/hour. If no toxicity was
observed during the first hour, then the dosage was
escalated by increments of 50 mg/hour every 30 min to a
maximum of 300 mg/hour. If the starting dose of rituximab
was well tolerated, then the starting flow rate for the
administration of the second and subsequent infusions was
fixed at 100 mg/hour, with similar increments at 30 min
intervals up to 400 mg/hour. The infusion was interrupted if
patients experienced severe fever, rigors, edema or mucosal
congestion, hypotension, or any other serious AEs. Following
resolution of the AEs, the infusion was to be resumed at half
the previous rate. The dose was not modified throughout the
treatment period. Administration of oral premedication with
acetaminophen at 1000 mg and diphenhydramine hydro-
chloride at 50–100 mg was recommended 30–60 min before
each infusion.
Of the 54 patients who were enrolled over a 6-month period,
36 were able to complete the 8-week treatment program. Five
patients achieved a complete response and 12 others a partial
response. The overall response rate was not statistically
significantly different between the two dosage groups.
All patients enrolled in this study received at least one
infusion of rituximab. Five patients did not experience any
infusion reactions. Altogether, the other 49 patients reported
168 infusion reactions, although nearly 90% of these
reactions were termed ‘mild to moderate’ in severity. In both
arms, the majority of AEs occurred during the first infusion
and resolved within the same outpatient treatment day. The
frequency of AEs and their severity decreased for the
subsequent infusions. Grade 3 and grade 4 AEs were seen
predominantly during or shortly after the first infusion. Two
deaths during the study period were reported, and both were
judged secondary to the study disease. Before death, both
patients had been withdrawn from the study because of
progressive disease.
In another study, Colombat and colleagues [4] recruited 49
patients with grade 1–3, stage II–IV follicular NHL. Ten
patients treated with rituximab achieved a complete response
rate and, overall, 39 patients (80% of the patients in the
study) achieved objective responses to treatment.
All patients in this trial were able to receive the four weekly
infusions at full dose. The most common AEs thought to be
related to rituximab infusions were grade 1–2 fever, head-
ache, asthenia, pain, rash, laryngitis, rhinitis, paresthesia,
hypotension, and nausea. Two cases of grade 3–4 hypo-
tension and hypertension resolved after appropriate
pharmacologic management, given in accordance with the
protocol procedures. No hematologic toxicity was observed
and only one minor infection was reported during the course
of the study.S21
Davis and coworkers [5] administered rituximab to 31
patients with follicular NHL, all of whom had previously under-
gone therapy. All patients received four rituximab doses. The
study found that 43% of patients achieved a response to
therapy. The time to response was similar to that observed in
patients without bulky disease who had been administered
rituximab with different treatment protocols.
About 93% of the clinical AEs were considered mild to
moderate, or grade 1 or 2. The majority of patients experienced
AEs during the first infusion, and incidence declined with
subsequent infusions. The most common related events
observed during the treatment period included transient fever
(61% of patients), chills (36%), leukopenia (23%), nausea
(19%), dizziness (19%), and throat irritation (19%). Grade 3
or 4 related nonhematologic clinical events occurred in four
patients: two with pulmonary disorders, one with chills, and
one with pain and infusion-related hypotension. The AEs
resolved in three of these four patients. No grade 3 or 4
infections were reported, and no patients were hospitalized
for infection; however, six infections reported in five patients
(pneumonia, rhinitis, sinusitis, herpes zoster, and
uncategorized infection) were treated subsequently without
incident. None of the patients in this study were forced to
discontinue treatment because of AEs.
Foran and colleagues [6] in London treated 131 patients with
mantle cell lymphoma, immunocytoma, and small B cell
lymphocytic lymphoma; these B cell malignancies express
CD20 and historically were incurable with standard therapy.
For this study, rituximab 375 mg/m2 was administered for
4 weeks as an intravenous infusion in 1 litre normal saline. Of
the 120 evaluable patients (11 could not be included in the
treatment response assessment because of treatment-related
toxicity, including one who died from splenic rupture), 36
(30%) achieved an objective response to rituximab. Although
10 patients achieved a complete response, most of the
enrollees had only a partial response to rituximab. Sixty-one
patients had stable disease, and 23 had evidence of
progressive disease (confirmed during therapy or at the
1 month restaging analysis).
All 131 patients were evaluated for toxicity. The infusions
were generally well tolerated, even though infusion-related
side effects such as fever, rigors, and nausea were relatively
common. These side effects occurred most frequently with
the first treatment, and in most cases they were managed
with adjustments to the infusion rate. The researchers noted
that the average duration of the first infusion was 5.2 hours
compared with 3.4 hours for subsequent infusions, reflecting
the requirement for fewer interruptions caused by adverse
reactions and a more rapid infusion rate in later weeks.
No evident excess in infusional toxicity was observed in the
10 patients presenting with a marked lymphocytosis (i.e.
>2 5×1 0 9/l), although one patient did experience a severe
anaphylactic-type reaction with the first infusion, which
necessitated its discontinuation. The latter patient was
subsequently able to complete treatment without further
reaction.
Eight patients did not finish therapy because of AEs,
including three who withdrew due to anaphylaxis/severe
allergic reactions. Others were withdrawn because of atrial
fibrillation, elevated serum liver function tests, syncope, and
urticaria. One patient with underlying diabetes mellitus and
extensive chemotherapy refractory mantle cell lymphoma died
from splenic rupture several hours after completing the first
infusion, which had been complicated by fevers, rigors, and
hypoglycemia.
The study uncovered 31 episodes of infection, most of which
were deemed mild or moderate in nature. Ten patients
suffered arrhythmias, which occurred along with or
immediately following infusion.
Long-term objective response
Hainsworth and coworkers selected rituximab for treatment of
patients with chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL) [7]. CLL, the common form of
leukemia, is derived from small B lymphocytes in the majority
of cases; SLL, which is usually characterized by predominant
adenopathy, contains small B lymphocytes that are
indistinguishable, histologically and immunologically, from
those seen in CLL. Treatment for both of these illnesses is
initiated for control of symptomatic or advanced disease,
because the disease course is indolent and asymptomatic for
long periods in a large percentage of patients. Several
cytotoxic agents exhibit activity as first-line therapy, but most
patients with CLL/SLL develop progressive resistance with
time to subsequent chemotherapeutic agents.
Forty-four patients with previously untreated CLL/SLL
received rituximab (375 mg/m2 weekly for 4 consecutive
weeks). Patients who achieved an objective response or
whose disease had stabilized continued to receive identical
4-week courses of rituximab at 6-month intervals, for a total of
four full courses of therapy. The first rituximab dose was
administered in a slow 6-hour infusion in all patients. The
infusion rate was increased beginning with the second dose
in 39 out of 44 patients. The infusion rate was begun at a
starting rate of 100 mg/hour, with a 100 mg/hour dose
escalation every 30 min to a maximum of 400 mg/hour. Many
oncologists use this rate only after the first infusion and use
half these rates on the first infusion day.
After the first course of treatment with rituximab, 51% of
patients achieved an objective response, including 4% who
had a complete response. With the inclusion of 28 patients
who received one or more additional courses of therapy, the
overall response rate reached 58%, with 9% complete
responses. At 1 and 2 years of follow up, 62% and 49% of
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patients, respectively, had progression-free survival, which
compares favorably with combination chemotherapy outcomes.
As with NHL patients, the rituximab therapy was well
tolerated. During the first course of rituximab two patients
experienced grade 3–4 infusion related toxicities during their
first infusion. One patient required a brief hospitalization for
symptomatic treatment of a severe headache, which subse-
quently resolved. Grade 1 and 2 infusion related toxicities
were relatively common during the first rituximab infusion but
were uncommon with subsequent infusions. All treatment-
related toxicities were reversible, and no patient was removed
from treatment because of toxicity.
Management of infusion-related side effects
Reactions to rituximab are unusual when compared with
experiences seen in other drugs. Most of the toxicity occurs
immediately and often with the initial dose of the medication.
These infusion reactions can be dramatic but are generally
easily controlled with additional medication. If clinicians
witnessed these reactions with drugs other than rituximab,
the usual response would be to withdraw the medication.
Those reactions include decreased blood pressure, fever,
angioedema, chills, and subjective bronchospasm, although
they are not usually accompanied by overt wheezing.
These adverse reactions actually remit rapidly upon
discontinuation of the drug infusion. With additional
premedication and resumption of the drug infusion, the risk
for reactions diminishes dramatically. Data on long-term
safety and re-exposure are available and indicate that infusion
reactions are well characterized, with a reduction in toxicity
with subsequent doses.
An analysis of infusion reactions that take place during the
usual four courses of treatment was conducted by
McLaughlin and coworkers [8], who looked at data from the
pivotal trial of rituximab in NHL. They found that approximately
72% of patients suffered an infusion-related reaction
following the initial infusion. About 90% of those infusion
reactions were grade 1 or 2 (approximately 45% were grade
2, and 45% were grade 1); 10% were grade 3 or 4. During
the second infusion about 28% of patients had reactions, and
more than half were grade 1 reactions; fewer than 10% were
grade 3 or 4. The percentage of adverse reactions also
dropped during the third infusion; 24% of patients suffered
reactions, 75% of which were grade 1. Similarly, 22% of
patients had a reaction to the fourth treatment, and again
75% were of a mild, grade 1 nature. Grade 3 or 4 reactions
in later infusions are very uncommon. In fact, with the
continuation of treatment, patients experience less and less
toxicity, which is contrary to what one would expect from a
traditional anaphylactic-type response. Most symptoms such
as bronchospasm, rigor, fever, and drops in blood pressure
will resolve if treatment is delayed for just 30 min after
additional medications.
In our experience these reactions are easily managed
medically, as follows. Patients are premedicated with aceta-
minophen and diphenhydramine before the first administered
dose of rituximab. Additional doses of acetaminophen,
hydrocortisone and diphenhydramine are available if the fever
or any type of bronchospastic symptom occurs. Although
rigors are not medically significant, they may be frightening to
patients. If rigors occur, we manage them with meperidine. If
a side effect occurs, then the infusion is stopped for
approximately half an hour, additional saline is given
intravenously, and the infusion resumes at a slower rate.
Clinicians may administer diphenhydramine and
hydrocortisone at that point to ensure that the infusion is
comfortable for the patient. When the patient’s condition has
returned to baseline the infusion may be resumed. We usually
start one step lower than the rate of infusion at the time of the
reaction. If there is no reaction at the lower step after
resumption of the infusion, then the rate can be increased
slowly again. It is often possible to continue to escalate the
infusion rate without further incident. It is even possible to
increase the rate again beyond the point at which the patient
had the initial reaction.
Fewer serious infections
In the original pivotal trial McLaughlin and colleagues [1]
followed patients with NHL who received 4 weeks of
rituximab therapy, and then subsequently followed them for a
year or more. Despite B cell depletion, there was no increase
in the incidence of infection, which had been a significant
concern when the drug was originally investigated.
Researchers suspected that the effectiveness with which
rituximab could deplete B cells would lead to an increased
risk for serious bacterial infection; however, follow-up data
showed that serious bacterial infection did not emerge in
these patients. Of 166 patients in the trial, only seven
episodes of grade 3 infection occurred, none were grade 4,
and the majority were typical of those common in normal
hosts (Table 1). Within the lymphoma population, this would
not be out of the normal range for infections.
Even when used with chemotherapy, the inclusion of
rituximab in the treatment regimen is not associated with
greater infection rates. Coiffier and colleagues [9] randomly
assigned previously untreated patients (aged 60–80 years)
with diffuse, large B cell lymphoma to receive either the
standard CHOP regimen or CHOP with rituximab. A total of
197 patients were given eight cycles of CHOP every
3 weeks, and a second group of 202 patients were assigned
to receive eight cycles of CHOP plus rituximab given on day
1 of each cycle. The rate of complete response was
significantly higher in the group that received CHOP plus
rituximab (76%) than in the group that received CHOP alone
(63%; P = 0.0005). Moreover, with a median follow-up period
of 2 years, event-free and overall survival times were
significantly higher in the CHOP plus rituximab group
(P < 0.001 and P = 0.007, respectively). The GELA (Groupe
Arthritis Research & Therapy    June 2005 Vol 7 Suppl 3 MohrbacherS23
d’Etude des Lymphomes de l’Adulte) group, which performed
the study, did not find any overall difference in the rate of all-
cause AEs between those patients receiving CHOP and
those receiving CHOP plus rituximab. Further scrutiny
revealed no differences in grade 3 and grade 4 infections
between the two patient cohorts.
Rare adverse events
Some serious AEs have occurred – even a few fatalities – in
patients with infusion reactions in clinical trials, although
these are rare (0.01% of patients) [10]. Eighty per cent of the
deaths, which occurred following the first infusion, were
characterized by more typical anaphylactic-type responses
such as hypotension, angioedema, bronchospasm, and
hypoxia – adverse reactions that often begin within
30 minutes to 2 hours of the infusion [10].
Some of the rarest serious AEs are not typical anaphylactic
reactions but are hematologic in origin. These reactions
usually occur in patients with high B cell counts in the range
of 20,000/µl to 100,000/µl, such as CLL patients, and in
patients with risk factors for cardiopulmonary disease and
who therefore would be more susceptible to bronchospasm
or hypotension [10]. Therefore, in patients with heavy disease
burden and/or cardiovascular risk factors, the drug is often
administered in smaller incremental doses initially. If these
infusions are performed safely, the remaining dose can be
given 2–3 days later without major risk.
Most rare and severe reactions occur with the first infusion.
As B cells clear after the first infusion, the risk factors for AEs
decline dramatically with further infusions [10]. Rheumatolo-
gists may be concerned about fatal infusion reactions with
rituximab treatment; however, the risk factors associated with
high B cell counts do not even exist in most RA patients.
There are other serious but not life-threatening AEs such as
severe mucocutaneous reactions (0.02%), which occur
1–13 weeks after treatment [10]. These uncommon disorders,
including paraneoplastic pemphigus (0.0008%), Stevens–
Johnson syndrome, and toxic epidermal necrolysis, may also be
manifestations of the patients’ underlying malignancies [10].
Prolonged use of rituximab
One of the major differences between use of rituximab in the
oncology setting and its use for rheumatologic diseases will
be the necessity for long-term, possibly life-long use of
rituximab. At present there are several ongoing clinical trials in
the USA and worldwide investigating rituximab maintenance
therapy from an efficacy and safety perspective. Most
patients have tolerated repeat courses of treatment without
further accumulated toxicity.
In recent research reported by Hainsworth and colleagues
[11] on the use of extended course rituximab for low grade
NHL, they demonstrated that prolonged B cell depletion over
2 years was not associated with cumulative toxicity or an
increased incidence of serious infections. Forty-one patients
with low grade NHL were first administered rituximab at a
dose of 375 mg/m2 every week for 4 weeks. At 6 weeks
patients were followed up for evaluation; if they responded to
treatment or their disease had stabilized, then subsequent
4-week cycles of rituximab were initiated at 7, 13, and
19 months. Following the 6-week evaluation period the
researchers reported that 25 out of 39 patients (64%)
achieved an objective response and 15% a complete
response [11]. At a median follow up of 8 months, 32 out of
39 evaluable patients were free of disease progression, and
1-year progression free survival occurred in 77%. When the
researchers evaluated the safety of the long-term regimen,
they found that grade 1 and 2 infusion related toxicities were
the only common side effects. No instances of either grade 3
or grade 4 toxicities or neutropenia were reported in the trial.
In an effort to determine whether the clinical and pharmaco-
kinetic characteristics of rituximab could be improved with
prolonged exposure to the drug, Ghielmini and coworkers
[12] enrolled 202 patients with newly diagnosed or
resistant/relapsed follicular NHL. After a standard induction
phase with rituximab 375 mg/m2 every week for 4 weeks,
patients who exhibited a response or whose disease had
stabilized at week 12 were randomly assigned to either
observation or a maintenance protocol of rituximab
375 mg/m2 every 8 weeks at months 3, 5, 7, and 9. At a
median follow up of 35 months from the initial induction
treatment, Ghielmini and colleagues noted that the median
event-free survival was 12 months and 23 months for the
observational and maintenance arms, respectively (P = 0.02).
For patients who responded at week 12, 56% were still in
remission at 12 months in the observational arm as compared
with 80% in the maintenance arm (P = 0.01). Patients
receiving standard therapy experienced a 17% rate of
hematologic toxicity, as compared with 18% among those in
the maintenance protocol. Two per cent of patients had
anemia, 3% leukocytopenia, 4% thrombocytopenia, and
9.4% experienced neutropenia.
Even though these patients were very effectively depleted of
their B cells for more than 6 months, they maintained normal
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Table 1
Rituximab in non-Hodgkin’s lymphoma pivotal trial: infections
Patients monitored throughout treatment and >1 year follow up
Despite B cell depletion, incidence of infection was not increased
Most infections were typical of those common in normal hosts
Predominantly bacterial 
Seven episodes of grade 3 infections
No patients experienced grade 4 infections
Data from McLaughlin and coworkers [1].S24
IgA and IgG levels, and only had an approximate 28% drop in
IgM levels. That drop, in our experience, does not appreciably
increase the risk for bacterial infection. A 20% decline in IgM
is considered within the normal range.
The study demonstrated that, in follicular NHL patients whose
condition remained stable or responded after standard
rituximab treatment, the addition of single doses at 2-month
intervals for four total doses significantly improved the
chances of remaining in remission at 1 year, without inducing
additional toxicity.
Hainsworth and colleagues [13] also studied the efficacy of
rituximab maintenance therapy versus retreatment at
progression among patients with indolent NHL. The study
participants – rituximab naïve patients with previously treated
follicular or small lymphocytic lymphoma – were treated with
a standard induction course of rituximab 375 mg/m2 weekly
for 4 weeks. Patients who responded or achieved
stabilization of disease were then randomly assigned to
receive either rituximab retreatment – another standard
4 week course of therapy – at the time of progressive disease
or maintenance therapy, defined as a 4-week course of
treatment every 6 months for 2 years. Of the 114 patients
who entered the trial, 90 (79%) patients achieved clinical
benefit with the first course of treatment, allowing 44 patients
to be randomized to maintenance therapy and the other 46 to
the rituximab retreatment arm.
The final overall response rates were 52% in the maintenance
arm and 35% in the retreatment arm. The median progression-
free survival, however, was 31.7 months for maintenance
patients versus 7.4 months for retreatment, which was
statistically significant (P = 0.007; Table 2). The improvement
seen with maintenance therapy also appears to have been
achieved without increases in AEs. This database of patients
who received rituximab for extended periods of time and
completed B cell depletion for extended periods suggests
that rituximab is effective at clearing malignant B cells, with
no significant additional toxicity. In addition, the retreatment
trial conducted by Hainsworth and coworkers demonstrated
a lack of cumulative toxicity and no increase in opportunistic
or bacterial infections.
Conclusion
The data from these clinical trials provide clinicians with
insight into the role of rituximab in the management of NHL
and autoimmune diseases. Although there is still controversy
regarding the ideal maintenance schedule, treatment data
from more than 370,000 treated patients attest to the long-
term safety of rituximab therapy (Table 3). These pivotal trials
conducted with rituximab revealed that most of the adverse
side effects occur with the first infusion and grow less
frequent with subsequent infusions. Also, the findings yield an
improved awareness of the correlation between AEs and a
high number of circulating malignant cells and heavy tumor
burden. In addition, toxicity decreases with subsequent
treatment doses.
In light of the low infection rates (including no increased risk
for opportunistic infection) observed in oncology patients
taking rituximab, there is preliminary evidence to suggest that
this agent will be acceptably safe for use in rheumatologic
diseases such as RA.
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Table 2
Rituximab maintenance versus retreatment: comparison of efficacy
Maintenance Retreatment  P
Overall response rate (%) 52%  35%  0.14
Complete response rate (%) 27%  4%  0.007
% in continuous remission 45%  24%  0.05
% remaining in continuous remission 23% 2%  0.03
Median progression-free survival (months) 31.7 7.4 0.007
Median duration of rituximab benefit (months) 31.7 27.4 0.94
Table 3
Reasons why oncology experience with rituximab is most
helpful
Non-Hodgkin’s lymphoma and autoimmune diseases have similarities
Provides information on chronic use
Provides a large safety database of >370,000 patient exposures
Provides 7 years of postmarketing experience
Extensive experience allows us to predict and manage infusion reactions
Low infection rate in oncology provides information on potential for
infection in rheumatoid arthritisS25
References
1. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS,
Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanil-
las F, et al.: Rituximab chimeric anti-CD20 monoclonal anti-
body therapy for relapsed indolent lymphoma: half of patients
respond to a four-dose treatment program. J Clin Oncol 1998,
16:2825-2833.
2. Hainsworth JD, Litchy S, Burris HA III, Scullin DC Jr, Corso SW,
Yardley DA, Morrissey L, Greco FA: Rituximab as first-line and
maintenance therapy for patients with indolent non-Hodgkin’s
lymphoma. J Clin Oncol 2002, 20:4261-4267.
3. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson
P, Lister A, Feuring-Buske M, Radford JA, et al.: Rituximab (anti-
CD20 monoclonal antibody) for the treatment of patients with
relapsing or refractory aggressive lymphoma: a multicenter
phase II study. Blood 1998, 92:1927-1932.
4. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P,
Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, et al.:
Rituximab (anti-CD20 monoclonal antibody) as single first-
line therapy for patients with follicular lymphoma with a low
tumor burden: clinical and molecular evaluation. Blood 2001,
97:101-106.
5. Davis TA, White CA, Grillo-López AJ, Velasquez WS, Link B,
Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R,
et al.: Single-agent monoclonal antibody efficacy in bulky non-
Hodgkin’s lymphoma: results of a phase II trial of rituximab. J
Clin Oncol 1999, 17:1851-1857.
6. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-
Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C,
Reyes F, et al.: European phase II study of rituximab (chimeric
anti-CD20 monoclonal antibody) for patients with newly diag-
nosed mantle-cell lymphoma and previously treated mantle-
cell lymphoma, immunocytoma, and small B-cell lymphocytic
lymphoma. J Clin Oncol 2000, 18:317-324.
7. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC,
Bradof JE, Greco FA; Minnie Pearl Cancer Research Network:
Single agent rituximab as first-line and maintenance therapy
for patients with chronic lymphocytic leukemia or small lym-
phocytic lymphoma. a phase II trial of the Minnie Pearl Cancer
Research Network. J Clin Oncol 2003, 21:1746-1751.
8. McLaughlin P, Hagemeister FB, Grillo-López AJ: Rituximab in
indolent lymphoma: the single-agent pivotal trial. Semin Oncol
1999, Suppl 14:79-87.
9. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R,
Morel P, Van Den Neste E, Salles G, Gaulard P, et al.: CHOP
chemotherapy plus rituximab compared with CHOP alone in
elderly patients with diffuse large-B-cell lymphoma. N Engl J
Med 2002, 346:235-242.
10. Genentech Inc: Rituxan [Package Insert]. San Francisco, CA:
Genentech Inc; 2004.
11. Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin PC
Jr, Bearden JD III, Richards P, Greco FA: Rituximab monoclonal
antibody as initial systemic therapy for patients with low-
grade non-Hodgkin lymphoma. Blood 2000, 95:3052-3056.
12. Ghielmini M, Schmitz SFH, Cogliatti S, Pichert G, Fey M, Bet-
tiches D, et al.:  Prolonged treatment with rituximab signifi-
cantly improves event free survival and duration of response
in patients with follicular lymphoma: a randomised SAKK trial
[abstract]. Blood 2002, 100:604a.
13. Hainsworth JD, Litchy S, Greco FA: Scheduled rituximab main-
tenance therapy versus rituximab retreatment at progression
in patients with indolent non-Hodgkin’s lymphoma (NHL)
responding to single-agent rituximab: a randomized trial of
the Minnie Pearl Cancer Research Network [abstract]. Blood
2003, 102:69a.
Available online http://arthritis-research.com/contents/7/S3/S19